Loading...

AAV platform

We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.

Read more

LentiVector® platform

We have built a sector leading lentiviral delivery system, LentiVector® platform which is already used in commercially available treatments.

Read more

Overview

Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.

Read more

Get in touch

Contact form

Press releases

Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy

26 July 2022

Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology

26 July 2022

Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers Squibb company; adding two new viral vector programmes for Bristol Myers Squibb CAR-T therapies

21 July 2022

Oxford Biomedica signs new three year agreement with AstraZeneca

01 July 2022

More press releases

Platform

Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.

Read More

Services

OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.

Read More

Latest annual report

Go to downloads

Sign up for email alertsGo

InvestorsGo

PipelineGo

Contact us Go